Treatment of Enterocutaneous Fistulas With Somatostatin

Hild, Pitt; Dobroschke, J; Henneking, K.; Rieck, Bernd

doi:10.1016/s0140-6736(86)92445-1

Cited by 14 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by di Costanzo and colleagues, 13 a mean output reduction of 70% on day 1 was found in 37 patients with external fistulae. The third uncontrolled somatostatin-14 study showed a similar reduction in fistula output, although this was not significantpancreatic fistulae, 64%; common bile duct fistulae, 88%; other gastrointestinal fistulae, 78% 31 (fig 8).…”

Section: Retrospective Studies (Level Iib Ebm) and Case Studies (Levementioning

confidence: 88%

Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data

Hesse

Ysebaert

Hemptinne

2001

Gut

View full text Add to dashboard Cite

Section: Retrospective Studies (Level Iib Ebm) and Case Studies (Levementioning

confidence: 88%

Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data

Hesse

Ysebaert

Hemptinne

2001

Gut

View full text Add to dashboard Cite

“…Somatostatin and octreotide acetate decrease intesti nal fluid volume, electrolyte, and digestive enzyme con centrations by inhibiting salivary, gastric, pancreatic and biliary secretions [4], Several investigators have reported a favorable response of ECF [6][7][8], including pancreatic fistulas [14], to intravenous somatostatin. However, oth ers could not confirm a favorable response [5], and Reasbeck [ 15] reported an increase in fistula volume output greater than basal after slopping this hormone, a 're bound effect'.…”

Section: Discussionmentioning

confidence: 99%

“…Somatostatin is a tetradecapeptide which inhibits salivary, gastric, pancreatic, and biliary secre tions [4], In several cases. ECF have been reported to close following a short course of therapy with intrave nous somatostatin [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Success of Prolonged Therapy with the Somatostatin Analog, Octreotide Acetate, in Recalcitrant Enterocutaneous Fistulas

et al. 1989

View full text Add to dashboard Cite

The somatostatin analog, octreotide acetate, has been reported to accelerate closure of enterocutaneous fistulas (ECF), and, if the closure does occur, it does so within 10 days of therapy. We report on the closure in 2 consecutive patients with recalcitrant, high output ECF after 4 and 6 weeks of octreotide acetate therapy. The changes in fistula output volume and content in response to the drug are described. Since long-term treatment with this drug is generally well tolerated and easy to administer, at least a 6-week course should be considered before resorting to surgical resection.

show abstract

“…Indeed, in uncontrolled studies, somatostatin has been reported to induced closure of intestinal and pancreatic fistulas (Di Costanzo et al 1982;Hild et al 1986). However, several failures of somatosta¬ tin therapy have been reported in patients with such fistulas (Kingsnorth et al 1986;Hey et al 1986).…”

Section: Bleedingfrom Peptic Lesionsmentioning

confidence: 99%

“…However, several failures of somatosta¬ tin therapy have been reported in patients with such fistulas (Kingsnorth et al 1986;Hey et al 1986). Furthermore, fistulas caused by chronic diseases, such as Crohn's disease, are not suitable for this form of treatment (Hild et al 1986). …”

Section: Bleedingfrom Peptic Lesionsmentioning

confidence: 99%

Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract

Lamers

1987

Acta Endocrinologica

View full text Add to dashboard Cite

Somatostatin is present in the gastrointestinal tract in appreciable amounts. The highest concentrations of the polypeptide are found in the stomach, the upper small intestine, and the pancreas. Within the gastrointestinal tract, somatostatin inhibits various functions, including endocrine and exocrine secretion, motility, blood flow, absorption, and growth. The polypeptide regulates these functions by endocrine, paracrine, neurocrine or luminal mechanisms. Abnormalities of endogenous somatostatin have been implicated in several gastrointestinal disorders, including the somatostatinoma syndrome, antroduodenal D-cell hyperplasia, peptic ulcer, obesity, and liver cirrhosis.Because of its potent inhibitory effects, somatostatin or somatostatin-analogues have been used as therapeutic agents in various clinical conditions, such as upper Schusdziarra & Schmid 1986). man. Clin Endocrinol (Oxf) 12: 269-275. Williams G, Anderson J V, Williams S J R 8c Bloom S R (1987): Clinical evaluation of SMS 201-995: longterm treatment in gut neuroendocrine tumours, effi¬ cacy of oral administration, and possible use in nontumoural inappropriate TSH hypersécrétion. Acta Endocrinol (Copenh). Suppl 286: 26-36.

show abstract

Treatment of Enterocutaneous Fistulas With Somatostatin

Cited by 14 publications

References 3 publications

Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data

Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data

Success of Prolonged Therapy with the Somatostatin Analog, Octreotide Acetate, in Recalcitrant Enterocutaneous Fistulas

Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract

Contact Info

Product

Resources

About